Posters will be presented daily from 12:30 pm - 2:45 pm in Hall B-E

Symposia

Saturday Morning (9:30 am - 12:00 noon)

Inverse agonism: translation to in vivo function

Chairs: James H. Woods and Richard Neubig

Current status of inverse agonism as a pharmacological and therapeutic tool. Graeme Milligan, Univ. of Glasgow, Scotland

Delta-opioid inverse agonists. Chris J. Evans, UCLA

Inverse agonists in chemokine receptors.  M.R. Brann, Acadia Pharmaceut.

Inverse agonists and competitive antagonists in benzodiazepine dependent monkeys.  Charles P. France, Univ. of Texas Hlth Sci. Ctr., San Antonio

Actions of hallucinogens and atypical antipsychotic drugs at serotonin receptors

Chairs: Bryan L. Roth and David R. Sibley

Atomic and molecular mechanisms of 5-HT2A receptor activation, targeting and trafficking. Bryan L. Roth, Case Western Reserve Univ. Med. Sch.

RNA editing and genomic polymorphisms: relevance for schizophrenia, atypical antipsychotics and  hallucinogens. Elaine Sanders-Bush, Vanderbilt Univ. Med. Sch.

Functional roles of 5-HT2A receptors in the prefrontal cortex. Rodrigo Andrade, Wayne State Univ. Med. Sch.
 

5-HT2A receptors in psychosis and antipsychotic treatments: insights from knockout mice. Jay Gingrich,  Columbia Univ.

Serotonin 2C receptor distribution in the ventral tegmental area.  Marcy J. Bubar,  Univ. of Texas Med. Br. at Galveston (Abstract 3105)

A pharmacology core curriculum: to be or not to be

Chairs: Patricia B. Williams and Gregory D. Fink

Introduction: More than facts: knowledge, skills and attitudes. Patricia B. Williams, Eastern Virginia Med. Sch.

The knowledge objectives and essential drug list. Gary Rosenfeld, Univ. of Texas-Houston Med. Sch.

A view from the top: a chairman speaks. Kenneth E. Moore, Michigan State Univ.

Teaching medical school pharmacology in the 21^st century – can a core knowledge base be defined? Eric P. Brass, Harbor-UCLA Med. Ctr.

Beyond medical schools: health professions with prescribing authority. Jean D. Deupree, Univ. of Nebraska Med. Ctr.

Two pore-domain potassium channels: background currents come to the fore

Chair: Steven J. Feinmark

The K_2p channels:  dedicated and dynamic potassium leak pathways.. Steven A. Goldstein, Yale Univ. Sch. of Med.

TREK and TASK channels:  structure, regulation, pharmacology and implications in disease states. Michel Lazdunski, CNRS, Valbonne, France

Mechano- and lipid-sensitive two pore-domain postaaium channels in the heart and brain. Donghee Kim, Finch Univ. of  Hlth. Sci.

Lipid-dependent modulation of TASK-1 function: is there a role in dysregulation of cardiac rhythm? Richard Robinson, Columbia Univ.

Functions of TASK channels in the mammalian central nervous system: modulation by protons, neurotransmitters and volatile  anesthetics. Douglas A. Bayliss, Univ. of Virginia

Use of genomic data on drug metabolizing enzymes and drug transporters to assess risk

Chairs: Richard T. Okita and Rebecca Blanchard
 

Building a pharmacogenetics database from scratch. Teri E. Klein, Stanford Univ.

Cytochrome P450 protein models for predicting metabolic events important in risk assessment, drug design and toxicology. Jeff Jones, Washington State Univ.

Genetic regulation of ABC transporters. John Schuetz, St. Jude Children's Research Med. Hosp.

Pharmacogenetics of human sulfotransferases.  Rebecca Blanchard, Fox Chase Cancer Ctr.

Identification and characterization of polymorphic variants of CYP3A5. Su Jun Lee, NIEHS, Research Triangle Park, NC (Abstract 9024)

Saturday Afternoon (3:00 pm - 5:30 pm)

Cannabinoids: pharmacological actions and interactions between endogenous brain cannabinoid and opioid systems

Chair: Steven R. Goldberg

Introduction. Recent progress in cannabinoid research. Steven R. Goldberg, NIH, NIDA, Baltimore

Preclinical pharmacology of natural and synthetic cannabinoids: tolerance, dependence and behavioral physiological actions. B.R. Martin, Virginia Commonwealth Univ.

Endogenous cannabinoid systems and brain-behavior mechanisms. Daniele Piomelli, UCI

Involvement of endogenous opioid systems in cannabinoid dependence. Rafael Maldonado, Univ. of Pompeu Fabra, Barcelona, Spain

Cannabinoid dependence in humans: role of endogenous opioid systems. Margaret Haney, New York State Psychiatric Inst. and Columbia Univ.

New developments in the search for natural and synthetic cannabinoids. A. Makriyannis, Univ. of Connecticut

Trophic effects of estrogen in the brain:  protection for memory, aging and neurodegenerative disease

Chairs: Cynthia M. Kuhn and Rochelle D. Schwartz-Bloom

Rapid signaling events mediate trophic actions of estrogen. Dominique Toran-Allerand, Columbia Univ.

Estrogen and neuroinjury. Patricia Hurn, Johns Hopkins Univ.

Estrogen is trophic for dopamine neurons: implications for Parkinson's disease and addiction. Eugene Redmond, Yale Univ.

Estrogen and cognitive performance: basic and clinical findings.  Robert B. Gibbs, Univ. of Pittsburtgh Sch. of Med.

Teaching pharmacology to diverse audiences

Chairs: Jack W. Strandhoy and Patangi K. Rangachari

Introduction. Jack W. Strandhoy, Wake Forest Univ. Sch. of Med.

PBL for undergraduate and graduate students: for the few and the many. Patangi K. Rangachari, McMaster Univ. Hlth. Sci. Ctr.

Designing facilities and programs to optimize education in the health professions. O. Theodore Wendel, Arizona Sch. of Hlth. Sci.

Inquiry-based teaching of pathophysiology and pharmacology to 11th and 12th grade students. Jeffrey L. Osborn, Trinity Col. and Academy

Tailoring problem based learning approaches to your audience. Ann Lambros, Wake Forest Univ. Sch. of Med.

G -protein-coupled receptor kinases:  hope or hype for heart failure

Chair: Susan F. Steinberg

The structural basis of subtype specific signaling of beta adrenoceptors in cardiac myocytes. Brian K. Kobilka, Stanford Univ.

Mechanisms of GRK regulation. Jeffrey L. Benovic, Thomas Jefferson Univ.

Distinct cardiomyocyte B1- and B2-adrenergic receptor signaling phenotypes to cAMP and other effectors.  Susan F. Steinberg, Columbia Univ.

New roles for GRK mediated beta-adrenergic receptor internalization in heart failure. Howard Rockman, Duke Univ. Med. Ctr.

Sunday Morning (9:30 am - 12:00 noon)

Developing novel antidepressant drugs

Chair: Irwin Lucki

How antidepressants work:  pathways to better drugs. Alan Frazer, Univ. Texas Hlth. Sci. Ctr., San Antonio

Cellular and molecular targets for antidepressant drugs. Julie Blendy, Univ. of Pennsylvania

PDE inhibitors as novel targets for antidepressants. James O'Donnell, Univ. of Tennessee Hlth. Sci. Ctr.

Pharmacogenetic targets determining antidepressant drug effects.  Irwin Lucki, Univ. of Pennsylvania

Modeling anhedonia:  reward deficits reversed by antidepressants. Athina Markou, The Scripps Res. Inst.

Developmental neurotoxicology induced by NMDA antagonists/GABA agonists

Chair: William Slikker

The importance of the NMDA receptor system to normal and abnormal development. William Slikker, NCTR/FDA, Jefferson, AR

Commonly used anesthesia protocol causes neuronal suicide in the immature rat brain. Vesna Jevtovic-Todorovic, Univ. of Virginia

Effect of chronic ethanol treatment on the expression of NR1 splice variants in fetal cortical neurons.  Meena Kumari, Kansas State Univ.

Chronic exposure to sodium channel and NMDA receptor blockers during development in rats and monkeys: long-term effects on cognitive function. Merle G. Paule, NCTR, FDA, Jefferson, AR  (Abstract 2714)

NMDA antagonists/GABA agonists exposure during development: unifying mechanism of action, species extrapolation and potential impact on children's health. John Olney, Washington Univ. Med. Sch.

Non-genomic effects of estrogen in  endothelial cells

Chairs: Edward J. Kilbourne and James K. Liao

Estrogen receptor signaling through phosphatidylinositol-3-OH kinase. James K. Liao, Harvard Med. Sch.

Estrogen stimulates endothelial eNOS through Hsp90 binding. Jeffrey R. Bender, Yale Univ. Sch. of Med.

Estrogen preserves endothelial cell form and function. Ellis R. Levin, Univ. of California at Long Beach and Long Beach Vet. Affairs Med. Ctr.

Estrogen receptors and the cell SRFC (steroid receptor fast-action complex). Philip W. Shaul, Univ. of Texas Southwestern Med. Ctr. at Dallas

Sex hormones and endothelin-TXA2 in Zucker diabetic rats. Adesuyi L. Ajayi, Texas Southern Univ. (Abstract 583)

Monday Morning (9:30 am - 12:00 noon)

Role of GABA-enhancing neurosteroids in neuropharmacology

Chair: Richard W. Olsen

GABA-A receptor subunit specificity in the physiological modulation by neurosteroids. Richard W. Olsen, UCLA

Neurosteroid effects on GABA-A receptor subunit plasticity: synaptic and extrasynaptic actions. Sheryl Smith, SUNY at Brooklyn

Can the anxiolytic and antidysphoric profile of SSRIS be related to their ability to increase neurosteroids active at GABA-A receptors? Alessandro Guidotti, Univ. of Illinois at Chicago

Endogenous GABAergic neurosteroids contribute to ethanol actions: mechanisms and significance. Leslie Morrow, Univ. of North Carolina at Chapel Hill

Trafficking of ion channels

Chair: Arthur M. Brown

Quality control in the ER: dislocation of integral membrane proteins and their processing in the cytosol. Ron R. Kopito, Stanford Univ.

Lipid rafts and membrane ion channels. Michael M. Tamkun, Colorado State Univ.

Ion channel clustering. Peter G. Shrager, Univ. of Rochester

HERG trafficking: pharmacological and physiological chaperones. Eckhard Ficker, Case Western Reserve Univ.

Pharmacological management of septicemia

Chair: J. Thomas Peterson

The biology of sepsis and appropriate preclinical models. Fletcher B. Taylor, Oklahoma Univ. Hlth. Sci. Ctr.

Anti-coagulant mechanisms in the treatment of sepsis. Charles T. Esmon, Oklahoma Univ. Hlth. Sci. Ctr.

Anti-inflammatory mechanisms in the treatment of sepsis. Peter A. Ward, Univ. of Michigan Med. Sch.

Establishing therapeutic efficacy and safety in the clinic - lessons learned. Charles J. Fisher, Abbott Labs.

Regulation and physiological functions of extrahepatic cytosolic sulfotransferases

Chair: Charles Falany

Structure and mechanism of sulfotransferases. Masahiko Negishi, NIH, NIEHS, 

Research Triangle Park, NC

Sulfation pharmacogenetics: genotype-to-phenotype studies. Richard Weinshilboum,

Mayo Fndn.

Expression of human sulfotransferases in bacteria, cell lines and mice for studying their role in the activation of mutagens and carcinogens. Hansruedi Glatt, German Inst. for Human Nutrition, Bergolz-Rehbrucke, Germany

Steroid sulfation in human extrhepatic tissues. Charles Falany, Univ. of Alabama at Birmingham

Physiologic functions of estrogen sulfotransferase as revealed by gene targeting in the

mouse. Wenchao Song, Univ. of Pennsylvania

Cyclooxygenase-2 and COX-2 inhibitors in cardiovascular disease

Chairs: Leslie J. Crofford and Ben Lucchesi

The place of COXIBs in the treatment of rheumatic diseases. Leslie J. Crofford, Univ. of Michigan

COX-1 and COX-2-derived prostaglandins in vascular biology. Tilo Grosser, Univ. of Pennsylvania

Prostaglandins and hypertension: implications for use of COXIBs. Tom Coffman, Duke Univ.

Does specific inhibition of COX-2 pose a cardiovascular risk or benefit? Carlo Patrono, Univ. of Rome

Tuesday Morning (9:30 am - 12:00 noon)

Molecular substrates of anxiety:  what have we learned from GABA_A receptor heterogeneity?

Chair: Phil Skolnick

Overview.  Phil Skolnick, DOV Pharmaceut., Inc.

Molecular pharmacology of GABA_A receptor heterogeneity. Hartmut W.M. Lueddens, Univ. of Mainz, Germany

Analysis of GABA_A receptor functions by knock-in point mutations. Uwe Rudolph, Univ. of Zurich, Switzerland

Subtype selective GABA_A receptor ligands: can the in vivo and in vitro pharmacologies be reconciled? Harry June, Indiana Univ. - Purdue Univ.

Searching for the "holy grail": can we develop anxioselective drugs? Arnold S. Lippa, DOV Pharmaceut., Inc.

Nicotinic receptors:  connecting basic science to therapeutic potential

Chairs: George J. Christ and Jerry J. Buccafusco

Honorary Chair: John P. Long

Crystal structure of AChBP. August B. Smit, Vrije Univ., Amsterdam, The Netherlands

Phenotypes of nicotinic receptor knock out mice. Lisa Marubio, Baylor Col. of Med.

Disease relevance: schizophrenia. Robert Freeman, Univ. of Colorado Hlth. Sci. Ctr.

The potential of nicotinic therapy for Alzheimer's Disease and aging-related cognitive impairment. Edward D. Levin, Duke Univ. Med. Ctr.

Nicotinic drugs improve learning and memory in non-human primates. Jerry J. Buccafusco,   Med. Col. of Georgia

Transgenic models of heart failure and heart failure therapeutics

Chairs: J. David Port and Joan Heller Brown

The role of HDACs in modulating cardiac hypertropy.  Timothy A. McKinsey, Myogen, Inc., Westminster, CO

Role of G-protein receptor kinases in modulating cardiac function and rescue of heart failure phenotypes. Walter J. Koch, Duke Univ. Med. Ctr.

Role of G-proteins in the heart failure phenotype. Gerald W. Dorn, Univ. of Cincinnati

Myocardial hypertrophy and failure induced by altered contractile proteins. Leslie A. Leinwand, Univ. of  Colorado

The PDZ binding motif of the beta2 adrenergic receptor modulates receptor trafficking and signaling in cardiac myocytes. Yan Xiang, Stanford Univ. (Abstract 8708)

Ophthalmic drug development:  new frontiers or me too?

Chair: Benjamin R. Yerxa

Ocular pharmacology, target diversity and drug development. Gary Novack, PharmaLogic Development, INc., San Rafael, CA

Mechanisms in the pathogenesis of age related macular degeneration. Marco Zarbin, UMDNJ

Preclinical studies in ophthalmology. Ward Peterson, Inspire Pharmaceut., Inc.

Development of antisense therapies for CMV retinitis and other ophthalmic diseases. Scott Henry, Isis   Pharmaceut., Inc.

Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals

Chair: David S. Riddick

Positive and negative transcriptional regulation of cytochromes P450 by polycyclic aromatic hydrocarbons. David S. Riddick, Univ. of Toronto

Down-regulation of constitutive and inducible cytochromes P450 by inflammatory mediators. Edward T. Morgan, Emory Univ.

DHEA suppresses CYP2C11 expression through a PPAR-independent mechanism. Russell A. Prough, Univ. of Louisville Sch. of Med.

Bile acid and nuclear receptor regulation of cytochrome P450 gene transcription. John Y.L. Chiang, Northeastern Ohio Univ.

Suppression of the human sterol 12α hydroxylase (CYP8B1) gene by interleukin-1ß (IL-1ß). Asmeen Jahan, Northeastern Ohio Univ. Col. of Med. (Abstract 7285)

Tuesday Afternoon (3:00 pm - 5:30 pm)

Animal models of neuropsychiatric diseases

Chairs: Frank I. Tarazi and Sabina Berretta

Mechanisms of behavioral hyperactivity in juvenile rats: implications for ADHD. Frank I. Tarazi, Harvard Med. Sch.

Modeling Huntington's Disease in the mouse: mechanistic and therapeutic insights. Susan Browne, Cornell Univ.

Role of subthalamic nucleus and substantia nigra pars reticulata in primate parkinsonism. Thomas Wichmann, Emory Univ. Sch. of Med.

Role of the amygdala in the pathophysiology of schizophrenia: a "partial" rodent model. Sabina Berretta, Harvard Med. Sch.

Isoform-specific regulation of adenylyl cyclases:  a new focus for drug discovery

Chairs: Ross D. Feldman and Paul A. Insel

Isoform-specific regulation of adenylyl cyclases by GPCRs. Daniel R. Storm, Univ. of Washington

Development of drugs targeted to specific adenylyl cyclase isoforms. Yoshihiro Ishikawa, UMDNJ

Tyrosine kinase regulation of adenylyl cyclase isoforms. Ross D. Feldman, John P. Robarts Res. Inst., London, ON

Stoichiometry and compartmentation of signaling via adenylyl cyclases. Paul A. Insel, UCSD

Vesicle monoamine transporters (VMATs)

Chair: Arnold E. Ruoho

Chemical neuroanatomy of the vesicular amine transporters: autonomous and distributed aminergic phenotypes in the mammalian nervous system. Lee E. Eiden, NIMH, NIH

The ligand binding sites and structure of VMAT2. Arnold E. Ruoho, Univ. of Wisconsin

Sch. of Med.

Mechanisms of coupling of H⁺ and substrate fluxes in transporters:  EmrE as a model

system.  Shimon Schuldiner, Hebrew Univ. of Jerusalem, Israel

Efflux mediated by VMAT2. Robert H. Edwards,  UCSF

VMAT2 as a human gene for narcolepsy and dopaminergic disorders:  extended human VMAT2 haplotypes, imprinting and relationships to mouse knockout models. George R. Uhl, NIDA, IRP, NIH, Baltimore 

Division Sessions

Sunday Morning (9:30 am - 12:00 noon)

Division for Pharmacology Education Session: Who controls and teaches pharmacology in the new integrated curriculum?

Multiple learning formats provide opportunities and challenges to teaching pharmacology. Jack W. Strandhoy, Wake Forest Univ.

Proposals for curriculum revision at Duke Medical School - their impact on pharmacology education. J. Victor Nadler, Duke Univ. Med. Sch.

Pharmacology in the medical school curriculum - experiences at Baylor College of Medicine. Janet L. Stringer,  Baylor Col. of Med.
 

Division for Drug Metabolism Platform Session:  Biotransformation and drug transport
Chairs:  Michael R. Franklin and Thomas R. Kocarek

Sunday Afternoon (3:00 pm - 5:30 pm)

Division for Toxicology Symposium: The dangers of designer drugs

Chair: Terrence J. Monks

Selective neurotoxic effects of drugs of the amphetamine type. George Ricaurte, Johns Hopkins Univ. Sch. of Med.

On the chemistry and heptaic metabolism of designer drugs of the ecstasy and new piperazine type. Hans H. Maurer, Univ. of Saarland, Homburg/Saar, Germany

MDMA metabolism in humans: pharmacodynamic and toxicological implications. Rafael de la Torre, Inst. Municipal D'Investigacio Medica, Barcelona, Spain

The neurotoxicity of metabolites of ecstasy. Terrence J. Monks,  Univ. of Texas at Austin

Division for Cardiovascular Pharmacology Best Paper Award Presentations

Chairs: Mariana Morris and John Kermode

  Graduate Student Presentations - 3:00 pm

Mechanisms of K_ATPopener-induced delayed cardioprotection. E.R. Gross, Med. Col. of Wisconsin.

 

Glucocorticoids decrease GTP cyclohydrolase and tetrahydrobiopterin-dependent vasodilation through glucocorticoid receptors. B.M. Mitchell, Med. Col. of Georgia.

 

17ß-estradiol treatment suppresses IL-1ß-mediated induction of cyclooxygenase-2 in rat cerebral blood vessels. J.A. Ospina, Univ. of California, Irvine.

    Postdoctoral Presentations - 4:00 pm

Stress-induced cardiovascular responses in oxytocin knockout (OTKO) mice: is there an antistress effect of oxytocin? I. Bernatova, Wright State Univ. Sch. of Med.

 

Diazoxide attenuates mitochondrial reactive oxygen species production and calcium overload in cardiac myocytes following oxidant stress. S. P. Jones, Johns Hopkins Univ.

 

Gene therapy of eNOS and MnSOD restores impaired wound healing in type 1 diabetes. J. -D. Luo, Michigan State Univ.

 

COX-2 is spatiotemporally implicated in HGF/SF-induced angiogenesis.  Possibility of chemoprevention by NSAIDs? S. Sengupta, MIT.

  Business Meeting - 5:30 pm

Division for Clinical Pharmacology Symposium: Adrenergic signaling pathways as a target for pharmacogenetic research

Chair:  Terrence F. Blaschke
 

Genetic variants of adrenergic receptor signaling components: an introductory overview.

   Paul A. Insel, UCSD

Assessing the impact of alterations in cellular adrenergic responses at a functional level:  the weakest link? Ross D. Feldman, John P. Robarts Res. Inst., London, ON

In vivo pharmacology of human adrenergic receptor polymorphisms. C. Michael Stein, Vanderbilt Univ.

Alternative splicing as a mechanisms for variation in drug response.  Darrell R. Abernethy, NIA, NIH, Baltimore, MD

Synergistic polymorphisms on the ß₁ and α_2c-adrenergic receptors and the risk of congestive heart failure.  Kersten Small, Univ. of Cincinnati Med. Ctr.

Division for Behavioral Pharmacology Symposium: Learning and cognition: behavioral, pharmacological and molecular relationships
Chair:  James E. Barrett

Introduction. James E. Barrett, Memory Pharmaceut.

Genetic approaches to study learning and memory. Theodore G. Abel, Univ. of Pennsylvania

Mechanisms of learning in young and aging hippocampus. John F. Disterhoft, Northwestern Univ. Med. Sch.

Calcium regulation and gene expression in aging-related memory impairment. Philip W. Landfield, Univ. of Kentucky

Drug Development for cognitive enhancement. Gregory M. Rose, Memory Pharmaceut.

Monday Afternoon (3:00 pm - 5:30 pm)

Division for Drug Discovery, Development and Regulatory Affairs Symposium: Clinical genomics: a source of pre-validated drug targets and smart drugs

Chair: Benjamin R. Yerxa

Using multiple founder populations to discover new drug targets. Michael R. Hayden, Univ. of British Columbia

The genealogic approach to finding human drug targets for human disease. Jeffrey Gulcher, deCODE Genetics, Rejkjavik, Iceland

Genetic profiling complex diseases for drug discovery and trials. Lindsay A. Farrer,  Boston Medical Ctr.

Developing haplotypes for personalized medicine and smarter clinical. trials. Clay Stephens,   Genaissance Pharmaceut., Inc.

Division for Drug Metabolism Symposium: Structural domains and motifs: functional implications for drug-sensing transcription factors

Chair: Masahiko Negishi

Domain analysis of the Ah receptor. Lorenz Pollinger, Karolinska Inst., Stockholm, Sweden

Multiple drug-binding orientations in the crystal structure of the nuclear orphan receptor, PXR. Matthew R. Redinbo, Univ. of North Carolina at Chapel Hill

Nrf2 and its protein-protein interactions regulate drug-dependent gene induction. Masayuki Yamamoto, Univ. of Tsukuba, Tsukuba, Japan

Mutational analysis of the nuclear orphan receptor CAR. Masahiko Negishi, NIEHS, NIH, Research Triangle Park

Division for Molecular Pharmacology Post Doctoral Award Finalists
Chair:  Rick Neubig

Milliseconds to medicines: regulators of G-protein signaling (RGS) as novel drug targets. Rick Neubig, Univ. of Michigan

Beta-arrestins regulate a Ra1GDS Ral effector pathway that mediates cytoskeletal reorganization. Moshmi Bhattacharya, John P. Robarts Res. Inst., London, ON (Abstract 9478)

Phosphorylation of AGS3 by tumor suppressor kinase LKB1: a potential mechanisms for regulation of AGS3-Giα interaction. Joe B Blumer, Louisiana State Univ. Hlth. Sci. Ctr. (Abstract 8083)

Prostaglandin E₂ induction of early growth response factor-1 by EP₄ prostanoid receptors via phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. Hiromichi Fujino, Univ. of Arizona Col. of Pharm. (Abstract 4907)

Gq coupled receptor mediated ERK and Akt activation is attentuated by expression of a peptide inhibitor of Gq in aorta vascular smooth muscle cells.  Jihee Kim, Duke Univ. Med. Ctr. (Abstract 5889)

Ryanodine receptor phosphorylation and diastolic function are increased by CAMKII in cardiomyocytes. Tong Zhang, UCSD (Abstract 7565)

Division for Systems and Integrative Pharmacology Symposium: Cocaine neuropharmacology:  integrating functional imaging and in vivo neurochemistry

Chairs: Leonard L. Howell and Michael Nader

Use of PET imaging to characterize cocaine-induced changes in dopamine D₂ receptors in nonhuman primates. Michael A. Nader, Wake Forest Univ. Med. Sch.

Effects of cocaine self-administration on dopaminergic function determined by in vivo microdialysis in conscious nonhuman primates. Charles W. Bradberry, Yale Univ. Sch. of Med.

Monoamine transporters and cocaine medication development in nonhuman primates: PET imaging and in vivo microdialysis. Leonard L. Howell, Emory Univ.

Cocaine-induced cerebral vasoconstriction determined by fMRI in humans. Marc J. Kaufman, McLean Hosp.

Neurochemical mechanisms mediating cue-induced cocaine craving in humans determined by PET imaging and fMRI. Anna Rose Childress, Univ. of Pennsylvania

Division for Neuropharmacology Symposium:  Club drugs – neuropharmacology:  new challenges

Chair:  Jerry Frankenheim 

The "club drugs" present new challenges. Jerry Frankenheim, NIDA, NIH

Neurotoxic amphetamines. Bryan K. Yamamoto, Boston Univ.

Functional consequences of MDMA abuse. John E. Mendelson, UCSF

GHB physiology and pharmacology. O. Carter Snead III, Univ. of Toronto

Hallucinogens: from LSD to mescaline. Gerard J. Marek, Pfizer, Inc.

Neurotoxicity of NMDA antagonists (ketamine, PCP, N20, ethanol) in the adult and developing brain. John W. Olney, Washington Univ.

Special Sessions

Friday Afternoon (2:00 pm - 6:00 pm)

Teaching Institute: Challenges in pharmacology graduate education

2:30 pm - 4:00 pm

A classical approach to teaching pharmacology to graduate students.  Barbara S. Beckman,  Tulane Univ.

A core curriculum for graduate studies at MUSC. Perry V. Halushka,  Med. Univ. of South Carolina

Experience with a core curriculum for graduate students at LSU/Shreveport: pros and cons. Sandra Roerig,  Louisiana State Univ. at Shreveport

Graduate student panel:

Lawrence P. Carter,  Univ. of Texas Hlth. Sci. Ctr. at San Antonio, Ted Price, Univ. of Texas Hlth. Sci. Ctr. at San Antonio, Laila Elsherif,  Univ. of Louisville

Graduate Student Colloquium:  Practical tips for success in pharmacology graduate program and beyond
4:30 pm - 6:00 pm

The importance of networking: establishing ifelines for long-term survival. Richard De La Garza,  Albert Einstein Col. of Med.

Information overload: swimming rather than sinking in the sea of knowledge. David B. Bylund, Univ. of Nebraska Med. Ctr.

Saturday Morning (8:30 am - 11:00 am)

Workshop: Securing your future through competitive grant writing

(Sponsored by the Committee on Minorities)

Moderator:  Sunny E. Ohia

Goal: To provide an opportunity for the panelists to discuss their experiences in securing funding from governmental and non-governmental sources based on winning grant proposals.

Funding opportunities at the predoctoral level. Ashiwel S. Undie, Univ. of Maryland Sch. of Pharmacy

Funding opportunities at the postdoctoral level. Richard De La Garza, II, Albert Einstein Col. of Med.

Funding opportunities at the faculty level. Rita J. Valentino, Children’s Hosp. of

Philadelphia

Sunday Afternoon (3:00 pm - 5:30 pm)

Symposium: Drug abuse as a gender issue

(Sponsored by the Women in Pharmacology Committee)

Chairs: Linda P. Dwoskin and Kathleen M. Kantak

Response to alcohol and alprazolam in women with potential risk factors for developing substance abuse problems. Suzette M. Evans, Columbia Univ. Col. of P and S

Sex differences in the anxiety-reducing effects of abused drugs. Marlene A. Wilson, Univ. of South Carolina Sch. of Med.

Gender differences in substance use disorders. Kathleen Brady, Med. Univ. of South Carolina

Sex differences in the acquisition, maintenance, reinstatement, and treatment of drug abuse: animal models. Marilyn E. Carroll, Univ. of Minnesota

Hormonal effects on withdrawal and smoking behavior with and without transdermal nicotine in pre- and post-menopausal women during short-term smoking cessation. Sharon Allen, Univ. of Minnesota

Sex differences and nicotine reinforcement in animals and humans. Nadia Chaudhri, Univ. of Pittsburgh